HUE025801T2 - Amidin funkciós csoporttal rendelkezõ hatóanyagok bioelérhetõségének javítása gyógyszerkészítményben - Google Patents

Amidin funkciós csoporttal rendelkezõ hatóanyagok bioelérhetõségének javítása gyógyszerkészítményben Download PDF

Info

Publication number
HUE025801T2
HUE025801T2 HUE07785614A HUE07785614A HUE025801T2 HU E025801 T2 HUE025801 T2 HU E025801T2 HU E07785614 A HUE07785614 A HU E07785614A HU E07785614 A HUE07785614 A HU E07785614A HU E025801 T2 HUE025801 T2 HU E025801T2
Authority
HU
Hungary
Prior art keywords
inhibitor
use according
inhibitors
bioavailability
medicaments
Prior art date
Application number
HUE07785614A
Other languages
English (en)
Inventor
Bernd Clement
Christiane Reeh
Original Assignee
Dritte Patentportfolio Beteili
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteili filed Critical Dritte Patentportfolio Beteili
Publication of HUE025801T2 publication Critical patent/HUE025801T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (6)

  1. Szíthatta 1mi igénvpomok ί. Az tt) képlesÊ N,Nmdihidrevktmídín alkalmazása
    m gÿ'ôgyhaîàsd anyag tmtldin hmkcios csoportjának heiyePexkejeként gyógyszerekben a gyógyhatású aovs'g bioaléthetoségènek javasára.
  2. 2. Az 1. Igénypont szerinti alkalmazás, azzal jellemezve, hogy a gyógyhatású anyag a kdve-kezok csoportjából válaszloti: pcoteáz Inhibitorok, DNS- & RNS-mterkaláió vegy8kt«k, viráiis enzimek inhibitora; és N-teetil-ö-aszpartát receptor aníagogiaták.
  3. 3 A 2. igénypont szerűm aikahuazús, azzal jeliofuezYe, hogy a proteáz inhibitor egy írotnbsn inhibitor, Xa Dktör inhibitora. Vii iakto< inhibitora vagy a kongóidéiba kaszkátl mindegyik proieázának inhibitora vagy mairigiáz inhibitor.
  4. 4. a 2. igénypont szerinti alkalmazás, azzal jellemezve, hogy a proteáz inhibitor egy nrokináz jnhMor,
  5. 5. A 2. igénypont szerinti alkalmazás, azzal jellemezve, hogy a DNS- és RNS-Iznerknláló vegyidet a peaiamiáin, dirmnazéo vagy ixommatnidlnet.
  6. 6. A 2. igénypont szerinti alkalmazás, azzal jellemezve, hogy a viráiis enzimek inhibitora egy nearaminiááz inhibitor. ?. A 2. igénypont szerűm alkalmazás az mi jellemezve. hogy a gyógyhatású anyag egy N-metll-D-axzpatíáz receptor atbagonista.
HUE07785614A 2006-07-21 2007-07-10 Amidin funkciós csoporttal rendelkezõ hatóanyagok bioelérhetõségének javítása gyógyszerkészítményben HUE025801T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006034256A DE102006034256A1 (de) 2006-07-21 2006-07-21 Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidinfunktion in Arzneimitteln

Publications (1)

Publication Number Publication Date
HUE025801T2 true HUE025801T2 (hu) 2016-04-28

Family

ID=38721771

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE07785614A HUE025801T2 (hu) 2006-07-21 2007-07-10 Amidin funkciós csoporttal rendelkezõ hatóanyagok bioelérhetõségének javítása gyógyszerkészítményben

Country Status (19)

Country Link
US (1) US20090270440A1 (hu)
EP (2) EP2987784A1 (hu)
JP (1) JP2009544588A (hu)
KR (1) KR20090075792A (hu)
CN (2) CN101506151A (hu)
AU (1) AU2007276526B2 (hu)
CA (2) CA2658434C (hu)
CY (1) CY1116941T1 (hu)
DE (1) DE102006034256A1 (hu)
DK (1) DK2046732T5 (hu)
ES (1) ES2555778T3 (hu)
HK (2) HK1210694A1 (hu)
HU (1) HUE025801T2 (hu)
PL (1) PL2046732T3 (hu)
PT (1) PT2046732E (hu)
SG (1) SG173401A1 (hu)
SI (1) SI2046732T1 (hu)
WO (1) WO2008009264A1 (hu)
ZA (1) ZA200901212B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
DE102008007440A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Aminosäurederivate als Arzneistoffe
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
DE102008061247A1 (de) 2008-12-10 2010-06-24 Christian-Albrechts-Universität Zu Kiel Inhibitoren der Dimethylarginin Dimethylaminohydrolase
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103864710B (zh) * 2014-03-24 2016-05-25 西安近代化学研究所 一种3-(3-氨基呋咱-4-基)-5-甲基-5-取代-4-羟基-4h,5h-1,2,4-恶二唑化合物的合成方法
CN103951660B (zh) * 2014-03-24 2016-07-06 西安近代化学研究所 一种恶二唑化合物的合成方法
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US6740682B2 (en) * 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US7157596B2 (en) * 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
US20040082585A1 (en) * 2001-10-03 2004-04-29 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade

Also Published As

Publication number Publication date
EP2046732A1 (de) 2009-04-15
CA2658434C (en) 2012-08-14
HK1210694A1 (en) 2016-05-06
SG173401A1 (en) 2011-08-29
AU2007276526A1 (en) 2008-01-24
DK2046732T5 (en) 2016-01-04
WO2008009264A1 (de) 2008-01-24
CN104644619A (zh) 2015-05-27
EP2046732B1 (de) 2015-09-09
US20090270440A1 (en) 2009-10-29
DE102006034256A1 (de) 2008-01-31
CY1116941T1 (el) 2017-04-05
ES2555778T3 (es) 2016-01-08
HK1221455A1 (zh) 2017-06-02
ZA200901212B (en) 2010-02-24
PL2046732T3 (pl) 2016-02-29
EP2987784A1 (de) 2016-02-24
PT2046732E (pt) 2016-01-06
CA2658434E (en) 2008-01-24
CA2777173A1 (en) 2008-01-24
CA2658434A1 (en) 2008-01-24
KR20090075792A (ko) 2009-07-09
AU2007276526B2 (en) 2011-08-11
DK2046732T3 (en) 2015-11-16
CN101506151A (zh) 2009-08-12
JP2009544588A (ja) 2009-12-17
SI2046732T1 (sl) 2016-02-29

Similar Documents

Publication Publication Date Title
HUE025801T2 (hu) Amidin funkciós csoporttal rendelkezõ hatóanyagok bioelérhetõségének javítása gyógyszerkészítményben
CN105007891B (zh) 新液体组合物的增强的稳定性
CN101287443B (zh) pH控制的脉冲释放系统、其制备方法和用途
CN102603723B (zh) 阿齐沙坦有机胺盐及其制备方法和用途
ES2567041T3 (es) Antagonista del receptor de angiotensina II para el tratamiento de diabetes mellitus en gatos
DK2249821T3 (en) Use of amidoximkarboxylsyreestre and N-hydroxyguanidin-karboxylsyreestre for the preparation of prodrugs
CN105412038A (zh) 一种包含沃诺拉赞和非甾体抗炎药的复方制剂
CN105407907A (zh) 尿酸值下降剂
BRPI0719236A2 (pt) Composições de carbamato de fenilalquila
CN101538218B (zh) 用于治疗或预防退行性和炎症性疾病的药物组合物
US20200289482A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
CN104055787A (zh) 药用水溶性抗真菌大分子化合物
CN102133180A (zh) 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法
CN101969941B (zh) 用作为药物的氨基酸衍生物
Pant et al. ORAL SUSTAINED RELEASE DRUG DELIVERY SYSTEM–A
EP3437641A1 (en) Inflammatory intestinal disease therapeutic agent
CN103228280A (zh) 包含瑞伐拉赞或其盐的可注射液体组合物
ES2770785T3 (es) Terapia de combinación
WO2022090605A1 (es) Derivado de andrografólido para su uso en el tratamiento de enfermedades inflamatorias asociadas a una tormenta de citoquinas
CN102048720A (zh) 丹参素、三七皂苷r1,及其配伍对微循环障碍引发的疾病的预防和治疗
JPH0158161B2 (hu)
Gonzalez et al. Articles in PresS. Am J Physiol Gastrointest Liver Physiol (November 20, 2014). doi: 10.1152/ajpgi. 00112.2013
KR20160027967A (ko) 전구약물을 생성하기 위한 아미드옥심 카르복실산 에스테르류 및 엔-하이드록시구아니딘 카르복실산 에스테르류의 용도
JP2006242688A (ja) 持続放出性製剤の薬物放出性の生体外評価方法